

WORLD HEALTH ORGANIZATION: MONOGRAPH SERIES

LYDIA B. EDWARDS, CARROLL E. PALMER  
& KNUT MAGNUS

# BCG VACCINATION

Studies by the  
WHO Tuberculosis Research Office,  
Copenhagen



WORLD HEALTH ORGANIZATION  
PALAIS DES NATIONS  
GENEVA

1953

Price : 15/- \$3.00 Sw. fr. 12.—

# BCG VACCINATION

Studies by the  
WHO Tuberculosis Research Office,  
Copenhagen

Report prepared under the direction of

**LYDIA B. EDWARDS, M.D.**

*Chief of Field Studies*

and

**CARROLL E. PALMER, M.D., Ph.D.**

*Director*

with the assistance of

**KNUT MAGNUS, cand. act.**

*Assistant Statistician*

*Tuberculosis Research Office, World Health Organization,  
Copenhagen*

WORLD HEALTH ORGANIZATION

PALAIS DES NATIONS

GENEVA

1953

NOTE

*Authors alone are responsible for views  
expressed in the Monograph Series of the  
World Health Organization.*

## CONTENTS

	Page
Introduction . . . . .	13
Chapter 1. Scope, methods, and material of the investigation .	17
Chapter 2. Pre-vaccination tuberculin sensitivity . . . . .	39
Chapter 3. Response to BCG vaccination . . . . .	51
Chapter 4. Effect of temperature and duration of storage of BCG vaccine . . . . .	65
Chapter 5. Effect of exposure of BCG vaccine to light . . . .	75
Chapter 6. Variations in the technique of intracutaneous BCG vaccination . . . . .	83
Chapter 7. Variations in the preparation of BCG vaccine . . .	97
Chapter 8. BCG vaccine from different production centres . .	105
Chapter 9. Effect of diluting BCG vaccine, and the significance of dead organisms . . . . .	125
Chapter 10. General summary . . . . .	143

## APPENDICES

General notes to Appendices I and II* . . . . .	148
Appendix I. Basic data for all studies . . . . .	149
Appendix II. Additional data from selected studies . . . . .	285
Appendix III. Measurement of leakage of tuberculin syringes . .	303

---

\* Detailed contents of Appendices I and II will be found on pages 150-153 and 286, respectively.

## FIGURES

	Page
1. Mean diameter of Mantoux reactions to 10 TU for 23 batches of Danish vaccine, according to date of retesting . . . . .	34
2. Differences in diameter of Mantoux reactions to 10 TU, as read by a trainee and an experienced reader, grouped according to size of reactions . . . . .	34
3. Differences in diameter of Mantoux reactions to 10 TU, as read by two pairs of experienced readers, grouped according to size of reactions . . . . .	35
4. Standard field record-card . . . . .	38
5. Frequency distributions of diameter of pre-vaccination Mantoux reactions to 10 (or 5) TU among schoolchildren in Denmark, Mexico, Egypt, and India . . . . .	41
6. Frequency distributions of diameter of pre-vaccination Mantoux reactions to 100 TU among schoolchildren in Denmark, Mexico, Egypt, and India who reacted with less than 6 mm of induration to 10 TU (or less than 5 mm of induration to 5 TU) . . . . .	43
7. Frequency curves, by age, of diameter of pre-vaccination Mantoux reactions to 10 (or 5) TU among schoolchildren in Denmark, Mexico, Egypt, and India . . . . .	44
8. Frequency curves, by age, of diameter of pre-vaccination Mantoux reactions to 100 TU among schoolchildren in Denmark, Mexico, Egypt, and India who reacted with less than 6 mm of induration to 10 TU (or less than 5 mm of induration to 5 TU) . . . . .	47
9. Frequency distribution of diameter of Mantoux reactions to 10 TU (typed according to density), 6-12 weeks after vaccination . . . . .	53
10. Frequency distribution of diameter of pre-vaccination Mantoux reactions to 10 TU . . . . .	53
11. Frequency distributions of diameter of Mantoux reactions to 10 TU at different intervals after vaccination (Study G I) . . . . .	55
12. Frequency distributions of diameter of Mantoux reactions to 10 TU, 10 weeks, one year, and two years after vaccination (Study A I) . . . . .	55
13. Frequency distribution of diameter of vaccination lesions 6-12 weeks after vaccination . . . . .	56
14. Frequency distribution of diameter of vaccination scars one year after vaccination . . . . .	57
15. Mean diameter of Mantoux reactions to 10 TU and of vaccination lesions 8-9 weeks after vaccination, according to temperature and duration of storage of vaccine (Studies A II and A III) . . . . .	67
16. Mean diameter of Mantoux reactions to 10 TU, 8-11 weeks and one year after vaccination, for 7 batches of vaccine from four laboratories, according to duration of storage at 2-4°C . . . . .	68
17. Mean diameter of scars one year after vaccination, for 7 batches of vaccine from four laboratories, according to duration of storage at 2-4°C . . . . .	69

	Page
18. Mean diameter of Mantoux reactions to 10 TU one year after vaccination, for 3 batches of vaccine, according to duration of storage at 2-4°C and 20°C . .	70
19. Frequency distributions of diameter of Mantoux reactions to 10 TU one year after vaccination, for vaccines from three laboratories, according to duration of storage at 2-4°C (Study H I) . . . . .	71
20. Frequency distributions of diameter of Mantoux reactions to 10 TU, 8 weeks after vaccination, according to duration of storage of vaccine at 2-4°C, 20°C, and 30°C (Study A II) . . . . .	72
21. Frequency distributions of diameter of Mantoux reactions to 10 TU, 9 weeks after vaccination, according to duration of storage of vaccine at 42°C (Study A III) . . . . .	73
22. Frequency distributions of diameter of wheals according to volume of vaccine injected superficially . . . . .	86
23. Mean diameter of wheals according to volume of vaccine injected and depth of injection . . . . .	87
24. Frequency distributions of diameter of wheals according to depth of injection of 0.1 ml of vaccine . . . . .	87
25. Frequency distributions of diameter of vaccination lesions, and frequency of local abscess and abnormal scar, according to depth of injection of vaccine (Studies F II and F III) . . . . .	93
26. Diameter of Mantoux reactions to 10 TU, 6-12 weeks after vaccination, for 21 batches of Danish vaccine: combined frequency distribution for all batches (A), and schematic curves for individual batches (B) . . . . .	107
27. Relation between mean diameter of Mantoux reactions to 10 TU and of vaccination scars one year after vaccination, for 18 batches of Danish vaccine . . . . .	110
28. Frequency distributions of diameter of Mantoux reactions to 5 or 10 TU, 6-12 weeks after vaccination, for vaccines from six laboratories . . . . .	111
29. Frequency distributions of diameter of Mantoux reactions to 5 or 10 TU, 9½ weeks, one year, and two years after vaccination, for vaccines from three laboratories . . . . .	112
30. Frequency distributions of diameter of vaccination lesions 6-12 weeks after vaccination, for vaccines from six laboratories. . . . .	113
31. Comparisons between single batches of non-Danish vaccines and concurrent batches of Danish vaccine . . . . .	115
32. Mean diameter of Mantoux reactions to 10 TU and of vaccination lesions, for a batch of Mexican (M) and a batch of Danish (D) vaccine, according to strength of vaccine (Study H V, Denmark) . . . . .	118
33. Mean diameter of Mantoux reactions to 5 or 10 TU and of vaccination lesions, for a batch of Indian (I) and a batch of Danish (D) vaccine, according to strength of vaccine (Study H III) . . . . .	119
34. Mean diameter of Mantoux reactions to 10 TU and of vaccination lesions 8½ weeks after vaccination, for a batch of Egyptian (E) and a batch of Danish (D) vaccine, according to strength of vaccine (Study H VI, Egypt) . . . . .	121
35. Mean diameter of Mantoux reactions to 10 TU and of vaccination lesions 12 weeks after vaccination, for a batch of Egyptian (E) and a batch of Danish (D) vaccine, according to strength of vaccine (Study B III, Egypt) . .	121
36. Frequency distributions of diameter of Mantoux reactions to 10 TU, 7 weeks after vaccination, according to strength of vaccine (Study D IV) . . . . .	126

	Page
37. Mean and standard deviation of frequency distributions of diameter of Mantoux reactions to 10 TU, according to strength of vaccine. . . . .	127
38. Frequency distributions of diameter of vaccination lesions, and frequency of ulcer and scab, 7 weeks after vaccination, according to strength of vaccine (Study D IV) . . . . .	128
39. Mean diameter of Mantoux reactions to 10 TU and of vaccination lesions 7 weeks after vaccination, according to strength of vaccine (Study D IV) . . . . .	128
40. Frequency distributions of diameter of Mantoux reactions to 10 TU, 7 weeks after vaccination, for living and dead (heat-treated) vaccine, according to strength of vaccine (Study D IV) . . . . .	129
41. Frequency distributions of diameter of Mantoux reactions to 10 TU, for living and dead (heat-treated) vaccine, at different intervals after vaccination (Study G I). . . . .	131
42. Mean diameter of Mantoux reactions to 10 TU, for living and dead (heat-treated) vaccine, according to strength of vaccine (Study D II) . . . . .	132
43. Mean diameter of vaccination lesions 10 weeks after vaccination, for living and dead (heat-treated) vaccine, according to strength of vaccine (Study D II) . . . . .	132
44. Frequency distributions of diameter of vaccination lesions 10 weeks after vaccination, for living and dead (heat-treated) vaccine, according to strength of vaccine (Study D II) . . . . .	133
45. Relation between size of Mantoux reactions to 10 TU and of vaccination lesions 10 weeks after vaccination, for different strengths of living and dead (heat-treated) vaccine (Study D II) . . . . .	134
46. Mean diameter of Mantoux reactions to 10 TU, 8½ weeks after vaccination, for living and mostly dead vaccine, according to strength of vaccine (Study D III) . . . . .	135
47. Mean diameter of Mantoux reactions to 10 TU, for living vaccine, according to strength, and for living and dead (heat-treated) vaccine mixed in different proportions (Study D I) . . . . .	136
48. Relation between size of Mantoux reactions to 10 TU and of vaccination lesions 8½ weeks after vaccination, for different strengths of living and mostly dead vaccine (Study D III) . . . . .	137
49. Relation between size of Mantoux reactions to 10 TU and of vaccination lesions 9½ weeks after vaccination, for different strengths of living vaccine, and for living and dead (heat-treated) vaccine mixed in different proportions (Study D I). . . . .	137
50. Relation between size of Mantoux reactions to 10 TU and of vaccination lesions 7 weeks after vaccination, for different strengths of living, heat-killed, light-killed, and light-exposed vaccines, and for standard-strength vaccine stored for one year (Study D IV) . . . . .	139

## TABLES

	Page
I. Character and extent of the studies . . . . .	18
II. Size and character of vaccination lesions at different intervals after vaccination (Study G I) . . . . .	57
III. Lymph-node findings in cervical and axillary regions 8½-11 weeks after vaccination . . . . .	58
IV. Correlation between size of tuberculin reactions and of vaccination lesions 11 weeks after vaccination (Study E I) . . . . .	59
V. Extent of studies on effect of temperature and duration of storage of vaccine . . . . .	66
VI. Size of tuberculin reactions and of vaccination lesions 8½ weeks after vaccination, and counts of viable bacillary units, according to duration of exposure of vaccine to sunlight (Study B I) . . . . .	76
VII. Size of tuberculin reactions and of vaccination lesions 12 weeks after vaccination (in Denmark and Egypt), and counts of viable bacillary units, according to exposure of vaccine to sunlight, skyshine, and indoor daylight in Egypt (Study B II) . . . . .	77
VIII. Size of tuberculin reactions and of vaccination lesions 9-12 weeks after vaccination (in Denmark and Egypt), and counts of viable bacillary units, according to exposure of vaccine to outdoor and indoor daylight in Egypt (Study B III) . . . . .	79
IX. Counts of viable bacillary units, according to exposure of vaccine to sunlight and skyshine in Denmark and Egypt, December 1951 . . . . .	80
X. Size of tuberculin reactions and of vaccination lesions according to strength and volume of vaccine injected (Study F I) . . . . .	89
XI. Size of tuberculin reactions and of vaccination lesions according to depth of injection of vaccine (Study F II) . . . . .	91
XII. Size of tuberculin reactions and of vaccination lesions according to depth of injection of vaccine (Study F III) . . . . .	92
XIII. Size of tuberculin reactions and of vaccination lesions according to time between transfers of maintenance culture used to prepare vaccine (Study E V) . . . . .	98
XIV. Size of tuberculin reactions and of vaccination lesions according to harvest time of culture used to prepare vaccine (Studies E III and E IV) . . . . .	99
XV. Size of tuberculin reactions and of vaccination lesions according to degree of growth of culture used to prepare vaccine (Study E II) . . . . .	100



	Page
XVI. Size of tuberculin reactions and of vaccination lesions according to duration of grinding of vaccine (Study E I) . . . . .	101
XVII. Size of tuberculin reactions and of vaccination lesions according to composition of vaccine diluent, temperature and duration of storage of vaccine (Study E I) . . . . .	101
XVIII. Extent of data on standard-strength vaccines from different laboratories	106
XIX. Size of tuberculin reactions 6-12 weeks, one year, and two years after vaccination, for 24 batches of Danish standard-strength vaccine . . .	108
XX. Size of vaccination lesions 6-12 weeks, one year, and two years after vaccination, for 24 batches of Danish standard-strength vaccine . . .	109

*WORLD HEALTH ORGANIZATION*

*MONOGRAPH SERIES*

No. 12

# **BCG VACCINATION**



# BCG VACCINATION

Studies by the  
WHO Tuberculosis Research Office,  
Copenhagen

Report prepared under the direction of

**LYDIA B. EDWARDS, M.D.**

*Chief of Field Studies*

and

**CARROLL E. PALMER, M.D., Ph.D.**

*Director*

with the assistance of

**KNUT MAGNUS, cand. act.**

*Assistant Statistician*

*Tuberculosis Research Office, World Health Organization,  
Copenhagen*

14.13.9313.  
W686  
WORLD HEALTH ORGANIZATION

PALAIS DES NATIONS

GENEVA

1953

NOTE

*Authors alone are responsible for views  
expressed in the Monograph Series of the  
World Health Organization.*

## COLLABORATORS

The investigations were undertaken under the joint auspices of the International Tuberculosis Campaign, the Danish Statens Seruminstitut, and the WHO Tuberculosis Research Office. The Tuberculosis Research Office was responsible for the planning and execution of the field programme, and the Statens Seruminstitut prepared and supplied the vaccine and tuberculin used and carried out the supplementary laboratory work. The salaries of the field personnel and their expenses were paid by the International Tuberculosis Campaign and later by the United Nations International Children's Emergency Fund.

The field staff, first headed by Dr. Inger Marie Thellesen, is now headed by Dr. Johannes Guld. The following doctors and nurses participated in the work at different times :

Dr. Johanne Weis Bentzon	Grethe Hagen	Solveig Midtgaard
Dr. Christian Rud	Lis Halkjær-Lassen	Elisabeth Nielsen
Agnete Andreasen	Birthe Johansen	Sigrid Nielsen
Helena Burzynska	Erna Kjølholt	Gudrun Kjær Poulsen
Edith Frederiksen	Minna Madsen	Signe Reinholdt

Dr. Knud Tolderlund, of the Statens Seruminstitut, was responsible for the preparation of the vaccine and tuberculin used and for the laboratory work. He was assisted by Dr. Inger Dragsted.

Dr. Phyllis Q. Edwards and Dr. I-Chin Yuan, of the Tuberculosis Research Office, assisted in preparing the manuscripts of the report, and Hans Jacob Kreyberg, cand. oecon., in compiling the statistical data.

Grateful acknowledgement is due to Dr. Johannes Holm, Director of the International Tuberculosis Campaign, and Dr. Georg Bindslev, Chief Physician, Krabbesholm, Denmark, for invaluable help and co-operation. Special mention also should be made of the assistance rendered by Chief Physicians, Dr. Gregers Falkenfleth and Dr. Tage Hyge, of Denmark.

---



## CONTENTS

	Page
Introduction . . . . .	13
Chapter 1. Scope, methods, and material of the investigation .	17
Chapter 2. Pre-vaccination tuberculin sensitivity . . . . .	39
Chapter 3. Response to BCG vaccination . . . . .	51
Chapter 4. Effect of temperature and duration of storage of BCG vaccine . . . . .	65
Chapter 5. Effect of exposure of BCG vaccine to light . . . .	75
Chapter 6. Variations in the technique of intracutaneous BCG vaccination . . . . .	83
Chapter 7. Variations in the preparation of BCG vaccine . . .	97
Chapter 8. BCG vaccine from different production centres . .	105
Chapter 9. Effect of diluting BCG vaccine, and the significance of dead organisms . . . . .	125
Chapter 10. General summary . . . . .	143

## APPENDICES

General notes to Appendices I and II* . . . . .	148
Appendix I. Basic data for all studies . . . . .	149
Appendix II. Additional data from selected studies . . . . .	285
Appendix III. Measurement of leakage of tuberculin syringes . .	303

---

\* Detailed contents of Appendices I and II will be found on pages 150-153 and 286, respectively.



## FIGURES

	Page
1. Mean diameter of Mantoux reactions to 10 TU for 23 batches of Danish vaccine, according to date of retesting . . . . .	34
2. Differences in diameter of Mantoux reactions to 10 TU, as read by a trainee and an experienced reader, grouped according to size of reactions . . . . .	34
3. Differences in diameter of Mantoux reactions to 10 TU, as read by two pairs of experienced readers, grouped according to size of reactions . . . . .	35
4. Standard field record-card . . . . .	38
5. Frequency distributions of diameter of pre-vaccination Mantoux reactions to 10 (or 5) TU among schoolchildren in Denmark, Mexico, Egypt, and India . . . . .	41
6. Frequency distributions of diameter of pre-vaccination Mantoux reactions to 100 TU among schoolchildren in Denmark, Mexico, Egypt, and India who reacted with less than 6 mm of induration to 10 TU (or less than 5 mm of induration to 5 TU) . . . . .	43
7. Frequency curves, by age, of diameter of pre-vaccination Mantoux reactions to 10 (or 5) TU among schoolchildren in Denmark, Mexico, Egypt, and India . . . . .	44
8. Frequency curves, by age, of diameter of pre-vaccination Mantoux reactions to 100 TU among schoolchildren in Denmark, Mexico, Egypt, and India who reacted with less than 6 mm of induration to 10 TU (or less than 5 mm of induration to 5 TU) . . . . .	47
9. Frequency distribution of diameter of Mantoux reactions to 10 TU (typed according to density), 6-12 weeks after vaccination . . . . .	53
10. Frequency distribution of diameter of pre-vaccination Mantoux reactions to 10 TU . . . . .	53
11. Frequency distributions of diameter of Mantoux reactions to 10 TU at different intervals after vaccination (Study G I) . . . . .	55
12. Frequency distributions of diameter of Mantoux reactions to 10 TU, 10 weeks, one year, and two years after vaccination (Study A I) . . . . .	55
13. Frequency distribution of diameter of vaccination lesions 6-12 weeks after vaccination . . . . .	56
14. Frequency distribution of diameter of vaccination scars one year after vaccination . . . . .	57
15. Mean diameter of Mantoux reactions to 10 TU and of vaccination lesions 8-9 weeks after vaccination, according to temperature and duration of storage of vaccine (Studies A II and A III) . . . . .	67
16. Mean diameter of Mantoux reactions to 10 TU, 8-11 weeks and one year after vaccination, for 7 batches of vaccine from four laboratories, according to duration of storage at 2-4°C . . . . .	68
17. Mean diameter of scars one year after vaccination, for 7 batches of vaccine from four laboratories, according to duration of storage at 2-4°C . . . . .	69